MorphoSys (MOR) PT Set at €65.00 by Royal Bank of Canada
A number of other equities analysts have also recently weighed in on MOR. Independent Research set a €110.00 ($127.91) price target on MorphoSys and gave the stock a neutral rating in a report on Friday, July 6th. Oddo Bhf set a €106.00 ($123.26) price target on MorphoSys and gave the stock a buy rating in a report on Monday, June 18th. Berenberg Bank set a €103.00 ($119.77) price target on MorphoSys and gave the stock a buy rating in a report on Thursday, August 2nd. Commerzbank set a €98.00 ($113.95) price target on MorphoSys and gave the stock a buy rating in a report on Tuesday, July 31st. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) price target on MorphoSys and gave the stock a buy rating in a report on Thursday, July 19th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of €95.80 ($111.40).
ETR MOR opened at €85.45 ($99.36) on Monday. MorphoSys has a twelve month low of €49.63 ($57.71) and a twelve month high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.